tasimelteon 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4820 609799-22-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tasimelteon
  • hetlioz
  • VEC-162
  • BMS-214778
an agonist at melatonin MT1 and MT2 receptors, these receptors are thought to be involved in the control of circadian rhythms
  • Molecular weight: 245.32
  • Formula: C15H19NO2
  • CLOGP: 1.89
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 38.33
  • ALOGS: -3.81
  • ROTB: 4

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.33 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 9.04 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.75 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 31, 2014 FDA VANDA PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Insomnia 349.49 43.12 167 2213 174698 50428046
Middle insomnia 338.54 43.12 81 2299 9840 50592904
Drug ineffective 324.66 43.12 279 2101 819054 49783690
Product dose omission issue 239.70 43.12 132 2248 183706 50419038
Incorrect product administration duration 212.10 43.12 55 2325 9220 50593524
Nightmare 173.55 43.12 53 2327 16033 50586711
Abnormal dreams 173.34 43.12 47 2333 9330 50593414
Somnolence 137.36 43.12 87 2293 154898 50447846
Initial insomnia 129.87 43.12 33 2347 5082 50597662
Therapeutic product effect delayed 97.97 43.12 22 2358 1999 50600745
Therapeutic product effect decreased 83.57 43.12 61 2319 135989 50466755
Poor quality sleep 69.53 43.12 27 2353 16619 50586125
Therapeutic product effect variable 48.13 43.12 11 2369 1079 50601665
Sleep disorder 47.59 43.12 31 2349 57252 50545492
Hypersomnia 47.28 43.12 20 2360 15294 50587450
Headache 43.91 43.12 82 2298 506453 50096291

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 468.84 61.78 275 1464 362895 29209893
Middle insomnia 404.66 61.78 88 1651 5620 29567168
Insomnia 268.53 61.78 121 1618 88640 29484148
Incorrect product administration duration 234.64 61.78 53 1686 3988 29568800
Nightmare 206.75 61.78 59 1680 11358 29561430
Product dose omission issue 158.22 61.78 87 1652 96296 29476492
Abnormal dreams 149.01 61.78 41 1698 6879 29565909
Somnolence 135.57 61.78 78 1661 93877 29478911
Therapeutic product effect decreased 113.81 61.78 48 1691 29403 29543385
Initial insomnia 106.20 61.78 26 1713 2749 29570039
Feeling abnormal 62.07 61.78 39 1700 54406 29518382

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 458.42 52.54 319 2184 839928 63656301
Middle insomnia 411.12 52.54 96 2407 12781 64483448
Incorrect product administration duration 371.55 52.54 84 2419 9674 64486555
Insomnia 329.06 52.54 157 2346 197679 64298550
Nightmare 266.11 52.54 75 2428 20918 64475311
Product dose omission issue 241.81 52.54 127 2376 194620 64301609
Abnormal dreams 211.61 52.54 54 2449 10302 64485927
Somnolence 153.20 52.54 96 2407 203549 64292680
Initial insomnia 122.08 52.54 31 2472 5773 64490456
Therapeutic product effect decreased 106.10 52.54 62 2441 115289 64380940
Therapeutic product effect delayed 75.76 52.54 18 2485 2541 64493688
Poor quality sleep 71.16 52.54 27 2476 18924 64477305
Headache 62.97 52.54 89 2414 529378 63966851

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05CH03 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Melatonin receptor agonists
FDA MoA N0000000250 Melatonin Receptor Agonists
FDA EPC N0000175743 Melatonin Receptor Agonist
CHEBI has role CHEBI:79046 melatonin receptor agonists

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Non-24 hour sleep-wake cycle indication 230496009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.05 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 5856529 Dec. 9, 2022 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 5856529 Dec. 9, 2022 TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON
4MG/ML HETLIOZ LQ VANDA PHARMS INC N214517 Dec. 1, 2020 RX SUSPENSION ORAL 5856529 Dec. 9, 2022 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 10149829 Jan. 25, 2033 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 10149829 Jan. 25, 2033 TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 10449176 Jan. 25, 2033 TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 10610510 Jan. 25, 2033 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON TO PATIENTS WITH A SMOKING HISTORY
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 10610510 Jan. 25, 2033 TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON TO PATIENTS WITH A SMOKING HISTORY
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 10945988 Jan. 25, 2033 TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 10980770 Jan. 25, 2033 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENISSYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON TO SMOKERS OR TO PATIENTS BEING TREATED WITH A CYP1A2 INHIBITOR
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 10980770 Jan. 25, 2033 TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON TO SMOKERS OR TO PATIENTS BEING TREATED WITH A CYP1A2 INHIBITOR
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 11285129 Jan. 25, 2033 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH BETA-ADRENERGIC RECEPTOR ANTAGONISTS
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 11285129 Jan. 25, 2033 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH BETA-ADRENERGIC RECEPTOR ANTAGONISTS
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 9060995 Jan. 25, 2033 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH FLUVOXAMINE
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 9539234 Jan. 25, 2033 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 9539234 Jan. 25, 2033 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 9549913 Jan. 25, 2033 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 9855241 Jan. 25, 2033 TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL RE46604 Jan. 25, 2033 TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ORALLY ADMINISTERING 20MG OF TASIMELTEON ONCE DAILY BEFORE BEDTIME
4MG/ML HETLIOZ LQ VANDA PHARMS INC N214517 Dec. 1, 2020 RX SUSPENSION ORAL 10149829 Jan. 25, 2033 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS
4MG/ML HETLIOZ LQ VANDA PHARMS INC N214517 Dec. 1, 2020 RX SUSPENSION ORAL 10610510 Jan. 25, 2033 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON TO PATIENTS WITH A SMOKING HISTORY
4MG/ML HETLIOZ LQ VANDA PHARMS INC N214517 Dec. 1, 2020 RX SUSPENSION ORAL 10980770 Jan. 25, 2033 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENISSYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON TO SMOKERS OR TO PATIENTS BEING TREATED WITH A CYP1A2 INHIBITOR
4MG/ML HETLIOZ LQ VANDA PHARMS INC N214517 Dec. 1, 2020 RX SUSPENSION ORAL 11285129 Jan. 25, 2033 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH BETA-ADRENERGIC RECEPTOR ANTAGONISTS
4MG/ML HETLIOZ LQ VANDA PHARMS INC N214517 Dec. 1, 2020 RX SUSPENSION ORAL 9539234 Jan. 25, 2033 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 9730910 May 17, 2034 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE USE OF TASIMELTEON WITH RIFAMPIN
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 9730910 May 17, 2034 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH RIFAMPIN
4MG/ML HETLIOZ LQ VANDA PHARMS INC N214517 Dec. 1, 2020 RX SUSPENSION ORAL 9730910 May 17, 2034 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE USE OF TASIMELTEON WITH RIFAMPIN
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 10610511 Oct. 10, 2034 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 10610511 Oct. 10, 2034 TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 11141400 Oct. 10, 2034 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 11141400 Oct. 10, 2034 TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
4MG/ML HETLIOZ LQ VANDA PHARMS INC N214517 Dec. 1, 2020 RX SUSPENSION ORAL 10610511 Oct. 10, 2034 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
4MG/ML HETLIOZ LQ VANDA PHARMS INC N214517 Dec. 1, 2020 RX SUSPENSION ORAL 11141400 Oct. 10, 2034 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 10376487 July 27, 2035 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 10376487 July 27, 2035 TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
4MG/ML HETLIOZ LQ VANDA PHARMS INC N214517 Dec. 1, 2020 RX SUSPENSION ORAL 10376487 July 27, 2035 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL 10179119 Aug. 29, 2035 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON
4MG/ML HETLIOZ LQ VANDA PHARMS INC N214517 Dec. 1, 2020 RX SUSPENSION ORAL 10179119 Aug. 29, 2035 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL Dec. 1, 2023 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME (SMS) IN PATIENTS 16 YEARS OF AGE AND OLDER
4MG/ML HETLIOZ LQ VANDA PHARMS INC N214517 Dec. 1, 2020 RX SUSPENSION ORAL Dec. 1, 2023 NEW PRODUCT
20MG HETLIOZ VANDA PHARMS INC N205677 Jan. 31, 2014 RX CAPSULE ORAL Dec. 1, 2027 THE TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME (SMS) IN PATIENTS 16 YEARS OF AGE AND OLDER
4MG/ML HETLIOZ LQ VANDA PHARMS INC N214517 Dec. 1, 2020 RX SUSPENSION ORAL Dec. 1, 2027 FOR THE TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME (SMS) IN PEDIATRIC PATIENTS 3 TO 15 YEARS OF AGE

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Melatonin receptor type 1A GPCR AGONIST Ki 9.45 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Melatonin receptor type 1B GPCR AGONIST Ki 9.80 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
D09388 KEGG_DRUG
4033173 VUID
N0000190488 NUI
4033173 VANDF
CHEBI:79042 CHEBI
CHEMBL2103822 ChEMBL_ID
C478745 MESH_SUPPLEMENTAL_RECORD_UI
7393 IUPHAR_LIGAND_ID
8985 INN_ID
DB09071 DRUGBANK_ID
SHS4PU80D9 UNII
10220503 PUBCHEM_CID
1490468 RXNORM
211275 MMSL
30166 MMSL
d08240 MMSL
015295 NDDF
702394009 SNOMEDCT_US
704468000 SNOMEDCT_US
C1313052 UMLSCUI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Hetlioz HUMAN PRESCRIPTION DRUG LABEL 1 43068-220 CAPSULE 20 mg ORAL NDA 34 sections
HetliozLQ HUMAN PRESCRIPTION DRUG LABEL 1 43068-304 SUSPENSION 4 mg ORAL NDA 34 sections